A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Study Summary

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).

Conditions

Advanced or Metastatic NRAS-mutant Melanoma

Interventions / Drugs

Naporafenib Dacarbazine Temozolomide Trametinib

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment78 participants

Primary Completion—

Lead SponsorErasca, Inc.

Data Retrieved2026-04-11 04:13:01.654201+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.